International drug pricing index plan sent to White House

HHS has sent its proposal to base certain drug prices on an international index to the White House last week, according to a report from The Hill.

The proposal, which was introduced in late 2018, would drop payment for certain Medicare Part B drugs––which are typically administered at a doctor’s office­­––30% by basing payments off international pricing models. The plan was expected to save $17.2 billion over five years, according to CMS. The idea was opposed by the pharma industry.

Since then, some speculated if the rule would ever be finalized, according to The Hill. However, with the proposal being sent to the White House for review, a final rule could be forthcoming. At least, the idea is moving forward with support from HHS Secretary Alex Azar, The Hill reported.

It is not known when the White House will review or make changes to the proposal.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

Mark Isenberg, executive vice president of Zotec Partners, discusses key developments that will reshape the specialty this year. 

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks.